ALBUQUERQUE, N.M., Nov. 26 /PRNewswire-FirstCall/ -- Biomoda, Inc. (OTC Bulletin Board: BMOD) (http://www.biomoda.com), maker of early-detection cancer diagnostic tests, has approved MicroCap Management as the front-runner of its full media campaign. MicroCap Management has created a strategic media plan that will provide a launch pad for present and future business driven by the progressive vision of Biomoda's Senior Executive Officers.
John Cousins, President of Biomoda announced, "MicroCap has the tools and connections to spread the word to the wider investment community about Biomoda and its potential." Alan Siegel, Managing Director of MicroCap Management, LLC stated: "We are thrilled to have Biomoda on board, and we're extremely enthusiastic about the future of this program."
MicroCap Management, LLC, headquartered in Orlando, Florida, is a Corporate Communications and Broker Relations firm that utilizes business-to-business marketing strategies and extensive relationships with major investment web portals to promote growth for publicly traded companies. Its Managing Directors possess 30+ years experience in marketing and advertising for OTC and Fortune 500 companies, and its highly trained Broker Relations staff has established relationships with broker/dealers nationwide, thereby providing maximum worldwide exposure to broker/dealers, investment bankers, wholesale and retail traders, as well as hedge fund managers and the global investment community.
MicroCap Management has its hands on the pulse of Wall Street, generating exposure and driving liquidity through its free Lead Generator Program and Broker Relations Campaigns; thereby creating a niche that traditional IR and PR firms haven't tapped.
MicroCap Management's core philosophy is to allow its corporate clients to focus on core business while managing its corporate communications and broker relations, and in doing so has frequently taken micro cap companies that were once acorns to a market penetration level of mature oak trees. As a side benefit, these strategies often assist in building the consumer markets as well, which in turn can contribute to increased shareholder equity.
Additionally, MicroCap Management's programs help companies meet pre-requisite criteria to qualify for listing on premier exchanges such as NASDAQ, AMEX and NYSE.
Biomoda's patented technology, a non-invasive cytology based assay, is designed for cancer screening of large populations at a reasonable cost. Current diagnostic methods for lung cancer, including CT scans and X-rays, often detect the disease only at more advanced stages and are relatively expensive.
|SOURCE Biomoda, Inc.|
Copyright©2007 PR Newswire.
All rights reserved